Overview

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Status:
Completed

Trial end date:
2017-09-13

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in participants with chronic hepatitis C virus (HCV) infection.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Sofosbuvir
Sofosbuvir-velpatasvir drug combination
Velpatasvir